<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858039</url>
  </required_header>
  <id_info>
    <org_study_id>X08-0296</org_study_id>
    <nct_id>NCT00858039</nct_id>
  </id_info>
  <brief_title>Cardiotoxicity of Adjuvant Trastuzumab</brief_title>
  <acronym>CATS</acronym>
  <official_title>Prediction of Cardiotoxicity Using Serum N-terminal Pro-B-type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Prince Alfred Hospital, Sydney, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Prince Alfred Hospital, Sydney, Australia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trastuzumab (HerceptinÂ®) increases the chances of cure in patients with Her-2 overexpressing
      early breast cancer. Unfortunately, both the chemotherapy drugs used in this setting
      (anthracyclines) and trastuzumab are known to cause cardiac dysfunction in a proportion of
      patients. Patients who develop heart problems when taking trastuzumab might have to stop this
      treatment, which could jeopardise their chances of cure. N-terminal pro-B-type natriuretic
      peptide (NT pro-BNP) is a cardiac biomarker that is measured in the blood, the levels of
      which have been shown to indicate the presence of heart failure. Some early research has
      suggested that there may be a correlation between elevated NT pro-BNP and heart damage due to
      cancer chemotherapy and also trastuzumab. Troponin is another substance measured in the blood
      that can indicate heart damage. Finally, certain variations in an individual's genetic makeup
      (called polymorphisms) could put them at increased risk of heart damage from trastuzumab.
      Here we are studying whether any of these factors (NT pro-BNP levels, troponin levels, or
      certain genetic polymorphisms) can accurately predict who is at highest risk of
      trastuzumab-related cardiotoxicity.

      The principal aim of this study is to evaluate the utility of NT pro-BNP as a predictive
      biomarker for the development of trastuzumab related cardiotoxicity (TRC). The investigators
      will also examine if single nucleotide polymorphisms in the HER2 gene or Fc-gamma-receptor
      genes predict for TRC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiotoxicity (Cardiac death; grade 3/4 arrhythmia or ischaemia; NYHA Class 3 or 4 heart failure decline in LVEF by &gt;10% to a level &lt;55%; decline in LVEF by &gt;5% to a level &lt;50%)</measure>
    <time_frame>Until 6 months after completing trastuzumab</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">220</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Her-2 positive ESBC</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human serum Human whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to tertiary referral medical oncology clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female 18 years or older

          -  Histologically confirmed, completely excised invasive breast cancer with Her-2
             overexpression

          -  Primary surgery less than twelve weeks prior to registration

          -  LVEF&gt;50% as assessed by transthoracic echocardiogram or gated heart pool scan

          -  Eastern Cooperative Oncology Group Performance Status 0-2

          -  Adjuvant systemic treatment plan comprises at least three cycles of anthracycline
             chemotherapy AND 52 weeks of trastuzumab

          -  Before patient registration, informed consent must be given according to local
             regulations.

        Exclusion Criteria:

          -  Pregnancy

          -  Distant metastases from breast cancer

          -  Any systemic chemotherapy prior to study entry
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Beith, MBBS FRACP PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sydney South West Area Health Service (Royal Prince Alfred Hospital)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Private Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Haematology Oncology Clinic</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2137</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bankstown Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Private Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutherland Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2232</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macarthur Cancer Therapy Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Cancer Care Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2750</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tweed Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrew Love Cancer Centre</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warnambool Hospital</name>
      <address>
        <city>Warnambool</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6805</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Prince Alfred Hospital, Sydney, Australia</investigator_affiliation>
    <investigator_full_name>Shom Goel</investigator_full_name>
    <investigator_title>Breast Oncology Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

